Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
This biotech leader continues to rack up clinical successes.
Overview
Argenx (NASDAQ: ARGX) already markets Vyvgart Hytrulo for treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), two rare chronic autoimmune diseases. It appears to be on track to add another approved indication for the drug.
On Aug. 17, 2026, Argenx announced positive results from a Phase 3 clinical study evaluating Vyvgart Hytrulo for adults with autoimmune myositis. Like gMG and CIDP, autoimmune myositis is a rare autoimmune disease. Around 100,000 people in the U.S. are affected by it. No targeted treatments are currently available.
Details
Wall Street celebrated the news, with the biotech stock jumping more than 20% in the days following Argenx's announcement. But there's a bigger story for the company than one late-stage win.
Source
Originally published at www.fool.com.